Establishment of Lavipharm, a company by the Lavidas’ family.
Launch of Digitaline, an innovative cardiovascular product, in Greece.
Launch of Nitroglycerin Controlled Release tablets, in Greece.
New era begins under the management of Dr. A. Lavidas.
Collaboration with L'Oréal - first to sell cosmetics through pharmacies, in Greece.
Inauguration of Plant for the production of drugs & cosmetics.
Establishment of R&D department focused on drug delivery technologies.
First international operation center established in Paris.
First to launch AVON products in Greece establishing door-to-door channel.
Joint Ventures with Synthélabo and L'Oréal Cosmetique Active Completion of a dedicated transdermal systems production unit in Greece Launch of proprietary dermocosmetic brand CASTALIA.
Establishment of state-of-the-art wholesaling and distribution center.
Listing on the Athens Stock Exchange First entrance in the international market, launch of proprietary nitroglycerin transdermal system in Italy and France CASTALIA dermocosmetic brand launched internationally.
Acquisition of US-based R&D unit specialized in TDDS Launch of patented acne epidermal patch, worldwide, by L'Oréal.
Exclusive licensing rights to manufacture and market Betadine® brand in Greece.
Acquisition of R&D companies (France and the USA) with expertise in SCF technologies.
Establishment of a new subsidiary, Pharma PLUS, focusing on creating a nationwide pharmacy network under a common brand.
FDA approval of proprietary fentanyl patch.
Fentanyl patch first launch in Greece.
Fentanyl patch launch in Germany.
Regulatory approval to market fentanyl patch in 20 countries.
Establishment of operation center in Italy.
Entry in the Urology Market in Greece.
Entry in the Rare Diseases’ market.
Manufacturing rights for rivastigmine patch.
Technology transfer for clonidine patch.
Exclusive distribution agreement with Zentiva in Greece.
Telemaque Lavidas takes helm of Lavipharm Group.
Lavipharm is celebrating 110 Years Innovation in Health.
Fentanyl patch consecutive launches in the EU, Latin America and Asia.
Acquisition of rights for clonidine patch.
Strategic alliance with Tikun Europe. Olam
Direct commercial activities for clonidine patch in Italy.
Launch of Lifelab CBD in Greece.